Overview
EN ISO 8871-4:2006 - "Elastomeric parts for parenterals and for devices for pharmaceutical use - Part 4: Biological requirements and test methods" (ISO 8871-4:2006) specifies biological safety requirements and validated test methods for elastomeric components used in primary pharmaceutical packaging and drug‑delivery devices. The standard defines extraction procedures, biological tests and reporting conventions to assess extractable endotoxins, bioburden, and toxicity of elastomeric parts such as closures, stoppers, needle shields and other rubber items in contact with parenteral products.
Key topics and technical requirements
- Scope and purpose: Biological evaluation of elastomeric parts intended for parenterals and pharmaceutical devices; guidance for selection and interpretation of tests based on material chemistry and exposure conditions.
- Extractable bacterial endotoxins: Annex A provides an extraction method (example: ~100 cm² of parts agitated in endotoxin‑free water, with detection by LAL per USP/Ph.Eur.). Results expressed as EU/cm² or EU/ml. Limits are to be agreed between supplier and user; test validation is required.
- Bioburden: Bioburden (cfu/cm² or cfu per part) is monitored; methods should be validated (ISO 11737-1 referenced). Acceptable limits are contractual between supplier and user.
- Toxicity testing strategy: A tiered approach - start with in vitro cytotoxicity (Annex B) using serum‑supplemented culture medium and specified extraction ratio; if in vitro fails, proceed to in vivo intracutaneous (Annex C) and systemic toxicity (Annex D) testing. Assessment criteria reference USP chapters <87> and <88> and ISO 10993-5.
- Test method validation and documentation: All methods and extraction procedures must be validated and reported, including sample/medium ratios, temperatures and extraction times.
Practical applications
- Ensures biological safety of elastomeric primary packaging for injectables (vials, prefilled syringes, stoppers, seals).
- Supports supplier qualification, incoming inspection and batch release testing for pharmaceutical manufacturers.
- Provides testing protocols for contract testing laboratories and QA/QC teams to demonstrate compliance with regulatory expectations for parenteral contact materials.
- Facilitates supplier–user agreements on endotoxin and bioburden limits and on appropriate biological test batteries for specific applications (e.g., freeze‑drying stoppers, small cavities).
Who should use this standard
- Elastomer/rubber manufacturers and formulators
- Pharmaceutical packaging suppliers and device OEMs
- Quality assurance, regulatory affairs and validation teams in pharma companies
- Contract testing and analytical laboratories
- Regulatory bodies reviewing primary packaging safety data
Related standards and references
- ISO 8871 (Parts 1–5) - related parts cover extractables, identification, particles and functional testing
- ISO 10993‑5 - in vitro cytotoxicity
- ISO 11737‑1 - microbiological methods for bioburden
- USP chapters <85>, <87>, <88> and Ph.Eur. 2.6.14 - bacterial endotoxins and biological reactivity tests
Keywords: elastomeric parts, parenterals, biological requirements, test methods, extractable endotoxins, bioburden, cytotoxicity, LAL, USP, ISO 8871-4.
